Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8904769 | 0.94 | PDE10A (0.48) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL2334595 | 0.88 | CYSLTR2 (0.52) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL1262322 | 0.86 | PDE10A (0.50) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL6798820 | 0.86 | CYSLTR2 (0.53) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL2913941 | 0.82 | PDE10A (0.61) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL8668220 | 0.81 | PDE10A (0.46) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL860157 | 0.81 | KCNH2 (0.58) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL4866792 | 0.81 | HRH1 (0.49) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL9598037 | 0.81 | CYSLTR1 (0.46) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL3028085 | 0.81 | PDE10A (0.46) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5270322-A | Imidazo[1,2-a]pyridines, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1993-12-14 | — | — | US | disclosed |
| EP-0555825-A1 | Imidazo(1,2-a)pyridines as angiotensin-II-antagonists | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CYP1A2 1331/4885CYSLTR2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.